COVID-19 rapid antigen test

Last updated

COVID-19 rapid antigen test
Lateral flow covid 19 negative and positive test.jpg
Negative (left, showing Control line) and positive (right, showing Control and Test lines) results
Synonyms SARS-CoV-2 or COVID-19 antigen test, rapid antigen detection test (RADT), lateral flow test (LFT), lateral flow device (LFD), antigen-detecting rapid diagnostic test (Ag-RDT), antigen rapid diagnostic test (Antigen-RDT), point of care (POC) test, rapid test [lower-alpha 1]
PurposeTo diagnose SARS-CoV-2 infections (COVID-19)
LOINC 94558-4, 95209-3, 96119-3, 97097-0

COVID-19 rapid antigen tests or RATs, also frequently called COVID-19 lateral flow tests or LFTs, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5–30 minutes. RATs have been used in several countries as part of mass testing or population-wide screening approaches. [1] Many RATs can be used for self-testing, in which an individual "collects their own specimen… and interpret[s] their test result themselves". [2]

Contents

False positives are very rare; the tests' specificity is 98%-99%. [3] [4] [5] However, the tests have a sensitivity of 70%-72%, [3] [4] [5] which is lower than COVID-19 polymerase chain reaction (PCR) tests' sensitivity of 88%-96%. [6] [7] [lower-alpha 2] Despite this, COVID-19 RATs remain valuable in finding people who would otherwise not know they were infected, helping to prevent further transmission. The tests are more sensitive in the symptomatic and transmissive stages of disease when the viral load is higher. [3] [4] [5] [8] [9]

Uses

Use in diagnosis

COVID-19 rapid antigen tests (RATs) have been widely used for diagnosis of COVID-19. The World Health Organization (WHO) COVID-19 Case Definition states that a person with a positive RAT (also known as an antigen rapid diagnostic test or Antigen-RDT) can be considered a "confirmed case of SARS-CoV-2 infection" in two ways. [10] First, the person with a positive Antigen-RDT could meet a "probable case definition" such as having recent loss of smell or taste without any known cause, or could meet certain "suspect criteria" such as having a severe acute respiratory illness. [10] Second, the person with a positive Antigen-RDT could be asymptomatic but a "contact of a probable or confirmed case." [10] Nevertheless, individual countries may have different case definitions of COVID-19; for example, in New Zealand a positive PCR test (not just a RAT) is necessary for a person to be considered a "confirmed case." [11]

Use in screening

Between 2020 and 2021, studies using mathematical models estimated the benefit of frequent RATs in screening populations for COVID-19. Paltiel et al studied a hypothetical college campus with 5000 students. [12] Screening all students every two days with a "low-sensitivity, high-specificity test" (such as a RAT) would be able to control an outbreak of COVID-19. [12] Mina et al theorized that higher-frequency screening using lower-sensitivity RATs may be more useful than lower-frequency screening using higher-sensitivity PCR tests because the former would "capture most infections while they are still infectious." [13] The quick results of RATs would serve to limit asymptomatic spread. [13] Larremore et al simulated various COVID-19 population screening strategies. [14] The researchers found that "effective screening depends largely on frequency of testing and speed of reporting and is only marginally improved by high test sensitivity." [14]

Humanitarian uses

In addition to routine community use, rapid tests have also been utilised as part of humanitarian efforts during the pandemic. Following the flooding in Jakarta in Indonesia on 2 December 2020, rapid tests were made available in flood shelters. [15] Furthermore, following the closure of national borders in Europe following the emergence of the Alpha variant just before Christmas 2020, nearly 6,000 lorry drivers were stranded without food, [16] effectively stopping Christmas food deliveries. Rapid tests were deployed by French firefighters within 24 hours at the Channel. Rapid tests enabled lorries to get on the road and complete their deliveries and return to their families for Christmas, demonstrating the potential global utility of having an easily implementable COVID-19 test. [17] [18] Médecins Sans Frontières strongly endorsed the use of rapid tests in lower- and middle-income countries, noting "COVID-19 antigen tests can deliver rapid and actionable results, ensuring timely identification of people infected with the virus at the community level". [19]

Use for "return to normal"

Spain became the first country to use rapid tests to facilitate a return-to-normal with rapid tests being widely available in pharmacies in December 2020, [20] and a free music concert held in Barcelona for individuals who took a rapid test. [21] A similar approach was taken in Albania to enable music festivals. [22] However, many experts were unsure of this approach believing that "rapid tests are not the solution to restart normal life" [23] but might be used in conjunction with other infection control techniques. [24]

Concerns about use

A certification of quality for a COVID-19 rapid antigen home test. COVID-19 rapid antigen test Certification.jpg
A certification of quality for a COVID-19 rapid antigen home test.

False negatives (low sensitivity)

Although the specificity of RATs are high (98%-99%), [3] [4] [5] in 2020 RATs were criticized for having a sensitivity as low as 50%; that is, if people with COVID-19 as determined by a positive PCR test were also tested with a RAT, about half the time the RAT would be negative. [25] [26] [27] As of 2022, systematic reviews determined that the pooled sensitivities of RATs were 70%-72%. [3] [4] [5] In one systematic review, the range of sensitivities across studies was 37%-90%. [3] As the World Health Organization (WHO) recommends RATs with "≥ 80% sensitivity", [28] many RATs do not meet the WHO recommendation.

In the systematic reviews, the sensitivity was higher for symptomatic people (76%-82%) than for asymptomatic people (57%-68%). [3] [4] [5] RATs were more sensitive when samples had more viral load, as measured by a low PCR "cycle threshold," and less sensitive when the samples had less viral load. [3] [4] [5]

A 2022 study followed 225 adults and children with COVID-19 over 15 days using PCR tests, viral cultures, and home RATs. [29] It found that the sensitivity of the RAT (Quidel QuickVue) increased from 0% two days prior to symptom onset or first positive PCR test to 77% four days after symptom onset or first positive PCR test, with an overall sensitivity of 50%. [29] Compared with PCR tests collected the same day, the RAT sensitivity was 64%; compared with viral cultures collected the same day, the RAT sensitivity was 84%. [29] The sensitivity of the RAT was lower in persons who were vaccinated against COVID-19 than in persons who were not vaccinated against COVID-19. [29]

Potential for false negative results due to new variants

In November 2020, a new, marginally more infectious strain of SARS-CoV-2 was identified in the United Kingdom, the SARS-CoV-2 Alpha variant. The strain rapidly spread around the world. With widespread global use of this form of COVID-19 testing, there was a concern that this variant would render rapid testing obsolete. As part of the UK's accelerated technology evaluation of lateral flow, within 24 hours Public Health England laboratories were able to confirm that RATs in global development were not affected (i.e., that they could identify the new variant). This was because rapid test generally targets the capsid protein and not the spike protein. [30] Some strains have been identified with a nucleocapsid mutation (D399N) that does decrease the sensitivity of at least one RAT (Quidel Sofia 2) up to 1,000-fold. [31] Fortunately, the frequency of mutation D399N was still relatively low globally at ~0.02% as of May 2021. [31] A study published in 2022 found that the sensitivities of six rapid antigen detection tests were 70.0%-92.9% for the Delta variant and 69.6%-78.3% for the Omicron variant across a range of viral loads; however, for Omicron samples with a low viral load, the sensitivities were 0.0%-23.1%. [32]

False positive results when instructions not followed

If a COVID-19 RAT is used outside manufacturer recommendations, the result can be false positive. Beginning in December 2020, TikTok videos demonstrated how to use soft drinks to create false positive COVID-19 RAT results. [33] Later, researchers found that introducing fruit juices, alcoholic beverages, bottled water, and other products directly into an Abbott Panbio COVID-19 RAT without the manufacturer's recommended buffer solution produced false positives. [34] In contrast, a different RAT (BD Veritor) produced no false positive results under the same conditions. [34]

Slow deployment and uptake

Some have raised concerns about the slow deployment and uptake of RATs, and the potential loss of life that might have occurred as a result. A modelling study in Canada estimated that half the deaths in care homes in British Columbia in 2020 could have been prevented if rapid testing had been available. [35]

Toxicity of components

Various concerns have been raised related to the safety of chemical components contained within RAT kits, which can be toxic to humans if not properly used. [36] On 24 February 2022, Health Canada issued a public advisory warning that there had been a recent increase in calls to poison control centers associated with RATs, which contained the preservatives [37] sodium azide and ProClin. [38]

Methods

An antigen is a foreign molecule or molecular structure that can cause an immune response. COVID-19 rapid antigen tests (RATs) detect antigenic proteins on the surface of or in the interior of the SARS-CoV-2 coronavirus. Of the COVID-19 RATs that had received an emergency use authorization (EUA) from the US Food and Drug Administration (FDA) by January 2022, all detected nucleocapsid proteins, and one also detected the receptor-binding domain of the coronavirus spike protein. [39] : Table S1  Similarly, almost all tests on the European Union common list of COVID-19 RATs target nucleocapsid proteins. [40]

Rapid antigen test functioning by lateral flow assay. Lateral Flow Assay.jpg
Rapid antigen test functioning by lateral flow assay.

A typical COVID-19 RAT is a lateral flow test (LFT). [39] : Table S1  [41] For an LFT, a liquid sample (such as from a nasal swab) is placed on a pad at one end of a porous paper-like strip. [42] [43] The liquid is pulled through the strip by wicking (capillary action), encountering different chemically-enhanced regions embedded within the strip.

First, at a "conjugate pad," soluble antibodies with gold nanoparticles are picked up by the liquid, attaching to any SARS-CoV-2 antigens present in the sample. [41] Then, at the test line (which may be labelled "T"), antibodies specific to SARS-CoV-2 are anchored to the strip; these bind to any SARS-CoV-2 antigens, capturing the associated nanoparticles. [41] Finally at the control line (which may be labelled "C"), antibodies that can attach to the antibodies with nanoparticles are anchored, capturing the remaining nanoparticles. [41]

If there are no SARS-CoV-2 antigens present, then the gold nanoparticles are carried by the liquid, continue through the test line, and then captured at the control line, showing a single indicating a negative test. However, if there are antigens present, then some of the nanoparticles will be stopped at the test line and the rest will be stopped at the control line, showing two lines indicating a positive test. [41] [42] [43]

History of development and deployment

2020

COVID-19 rapid test being administered in Rwanda Covid-19 rapid test in Rwanda.jpg
COVID-19 rapid test being administered in Rwanda

In May 2020, the US Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a COVID-19 RAT, the Sofia 2 test manufactured by Quidel. [44]

In August 2020, the United States Department of Health and Human Services announced that the US government would be purchasing 150 million BinaxNOW RATs produced by Abbott Laboratories "to expand strategic, evidence-based testing." [45] Later the agency announced that 100 million of the tests were to be sent to governors to use "at their discretion," for example to reopen schools. [46]

By September 2020, it was reported that the United Kingdom's Moonshot program would be investing £100 billion to systematically assess, develop and implement new technologies for COVID-19 testing, including RATs for COVID-19. [47] In that month, the World Health Organization (WHO) released interim guidance on COVID-19 "antigen-detecting rapid diagnostic tests" (Ag-RDTs) including recommendations for their use, selection, and implementation. [48] The interim guidance noted that Ag-RDTs were easier to implement and less expensive than nucleic acid amplification tests (NAATs). [48] The World Health Organization (WHO) recommended the use of Ag-RDTs in outbreaks, in monitoring disease trends, and in early identification of cases. [48]

Health Canada approved its first COVID-19 RAT in October 2020, the Abbott Panbio test. [49] As of October 2020, there were questions in the US as to whether manufacturing capacity could keep up with the potential demand for hundreds of millions of RATs. [50] [51] RATs began to be rolled out across Portuguese schools and care homes. [52]

One of the early large studies of COVID-19 lateral flow devices (LFDs) was completed by Public Health England and University of Oxford, with a preliminary report released in November 2020. [53] The researchers undertook an evaluation of 64 LFDs that proceeded in several phases. [54] Of the four LFDs with "desirable performance characteristics," one (Innova) had a sensitivity of 78.8% and a false positive rate of 0.32%. [54]

Contents of a box of free COVID-19 rapid antigen lateral flow tests provided by the NHS Test and Trace system. NHS COVID-19 Rapid Antigen Test Kit 2.jpg
Contents of a box of free COVID-19 rapid antigen lateral flow tests provided by the NHS Test and Trace system.

On 2 November 2020, Slovakia became the first country in the world to initiate country-wide mass testing using rapid tests. Five million rapid tests were performed by 60,000 staff who used the SD Biosensor antigen test and performed swabbing on the population. [55] [56] Two research studies on the Slovakia experience were published in early 2021, one by professor Martin Kahanec from Central European University and his coauthors and another one by Martin Pavelka from the London School of Hygiene & Tropical Medicine and his team. Both studies suggested that rapid antigen mass testing helped to suppress the pandemic in the country, although according to the former study the effect of mass testing on the pandemic was temporary and started to dissipate after about two weeks. [1] [57]

The United Kingdom continued their ongoing rapid test development programme using the Innova rapid test, with increasing urgency as COVID-19 cases increased across Europe. On 6 November 2020, the Prime Minister, Boris Johnson, started city-wide screening of Liverpool as part of the accelerated technology evaluation. [58] [59] Further expansion of rapid tests pilots were also launched for many sectors where testing had not been previously available. These included students at Universities who had been particularly hit by outbreaks. This initially started at Durham University, who had the infrastructure and expertise to manage the rapid test programme, [60] but was expanded to the majority of UK universities and enabled the national evacuation-style plan to get students safely home for Christmas. [61] Rapid tests were also implemented within the National Health Service (NHS) for staff to reduce possible transmission to patients, [62] local authorities [63] and care homes to enable visits to visit residents. [64] [65] On 18 November 2020, Wales completed the first whole borough testing at Merthyr Tydfil. [66] [67]

Global efforts to step up evaluations of rapid tests were initiated by the World Health Organization (WHO) Emergencies Department who launched a major rapid diagnostic test implementation project on 10 November 2020, aided by agreement from the Bill and Melinda Gates Foundation that limited costs for low- and middle-income countries. [68] [69]

Austria started country-wide mass testing on 5 December 2020 and ordered seven million tests consisting of the SD Biosensor test and Siemens Clinitest (aka Orientgene). [70] [71]

By the middle of December 2020, there were many studies confirming the efficacy and success of using rapid tests to identify individuals with COVID-19 including studies in the Netherlands, [72] the United Kingdom, [73] and the US. [74] These studies all enabled rapid tests to enter standard national COVID-19 testing strategies. Global piloting of rapid tests was now common place in schools in Canada, [75] travel hubs in Indonesia, [76] and across India. [77]

Professor William A. Haseltine of Harvard said that "rapid, self-administered testing could stem the ever-surging tide of disease and death." [78] However, further deployment of rapid tests as part of mass testing approaches in the US stalled as a result of the impasse around the $900 billion in COVID-19 relief contained within the Consolidated Appropriations Act, 2021. The bill was criticized for not specifically supporting COVID rapid self-tests. [79] Meanwhile, the FDA authorized the Abbott BinaxNOW RAT "for prescription use at home." [80] [81] Subsequent approval was given for the first COVID-19 at-home RAT available without a prescription, by Ellume. [82]

In the UK in December 2020, the Medicines and Healthcare products Regulatory Agency approved the Innova rapid test for self-testing of asymptomatic people. [83] The United Kingdom's chief clinical medic, Dr Susan Hopkins, noted that rapid tests provided a means to find "people that...we couldn't otherwise find". [84]

Noting the ability to identify cases more rapidly, and considering the ensuing escalation in cases in Europe, the European Commission (EC) met in December 2020 and developed a common European framework for "use, validation and mutual recognition of rapid tests", committing 100 million euros for the purchase of tests from Roche and Abbott. [85] Stella Kyriakides, commissioner for Health and Food Safety, said "Rapid antigen tests offer us speed, reliability and quick responses to isolate COVID cases. This is crucial to slow down the spread of the pandemic." [85]

2021

By January 2021, the Council of the European Union advocated greater use of rapid tests, noting that "should research prove that rapid antigen tests can be conducted by the testee themselves.... self-testing with or without professional guidance could also be considered." [86] In the US, newly inaugurated US president Joe Biden released a national strategy for COVID-19 that pledged to "fund rapid test acquisition and distribution for priority populations, work to spur development and manufacturing of at-home tests and work to ensure that tests are widely available." [87] In March 2021, the US FDA authorized the Abbott BinaxNOW RAT and the Quidel QuickVue RAT for use at home without a prescription. [88]

Innova voluntarily launched a Class I recall in the US of more than 77,000 of its RATs in April 2021. [89] Two months later, the FDA warned Americans to stop using the test because it had "significant concerns that the performance of the test has not been adequately established." [89] A week after the FDA's warning about the Innova test, UK's Medicines and Healthcare products Regulatory Agency (MHRA) cleared the rapid diagnostic's use and extended its authorization. [90]

In October 2021, the World Health Organization (WHO) updated its interim guidance on Ag-RDTs. [28] Among other changes, the 2021 WHO interim guidance included updated information on test performance, uses selection, and storage. [28] Also in October 2021, Ellume recalled more than 2.2 million of its home tests because of "higher-than-acceptable false positive test results for SARS-CoV-2". [91]

In December 2021, US president Biden announced that the government planned to purchase and distribute for free 500 million at-home COVID-19 RATs. [92] In response, Dr Leana Wen was quoted as saying that the number of tests "does not come even close to what's needed." [92]

2022

US president Biden announced in January 2022 the purchase of 500 million additional RATs for free distribution. [93] In March 2022, the World Health Organization (WHO) issued interim guidance on self-testing with Ag-RDTs. [2] The WHO made a strong recommendation that COVID-19 Ag-RDT self-testing "should be offered in addition to professionally administered testing services." [2] An April 2022 warning from the US FDA concerned two counterfeit at-home COVID-19 RATs. [94]

2024

In October 2024, the US Food and Drug Administration granted marketing authorization for the Healgen Rapid Check COVID-19/Flu A&B Antigen Test. [95] The test, authorized for use without a prescription, is for use by individuals experiencing respiratory symptoms and uses a nasal swab sample to deliver at-home results in approximately 15 minutes for COVID-19 and influenza (flu). [95] The test detects proteins from both SARS-CoV-2 (the virus that causes COVID-19) and influenza A and B (the viruses that causes flu). [95] This is the first over-the-counter (OTC) test that can detect influenza to be granted marketing authorization using a traditional premarket review pathway, which enables the test to be marketed in the absence of an applicable emergency use declaration. [95] Other OTC flu/COVID tests are available under emergency use authorization. [95]

Economic aspects

Costs and cost-effectiveness

In late 2020, it was noted that in the US RATs cost US$5-$23, in contrast with PCR tests which cost at least $75. [50] In a Danish study published in 2021, RATs cost about $5.70 per test, as opposed to PCRs at $10.80 per test. [96] A 2021 study from Germany found that monitoring health care workers exposed to COVID-19 with RATs saves money compared with sending them into quarantine. [97] A 2021 study concluded that if the US is willing to pay $100,000 per year of life lost averted, then weekly or monthly testing of the population using RATs is likely to be cost-effective. [98] Another 2021 study estimated incremental cost-effectiveness ratios of "$7890 per infection averted and $1 430 000 per death averted" if weekly screening with home-based RATs were performed in the entire US population over a 60-day period. [99]

Global market value

Estimates of value of the worldwide market for RATs vary. One estimate was that the market size was $28 billion in 2021 with a compound annual growth rate (CAGR) of -21.7%, leading to a size of $14 billion in 2028. [100] A second estimate suggested that the market value was $4.6 billion in 2021, with a CAGR of -26.3%, leading to a value of $743 million in 2027. [101] A third estimate found a value of $5.3 billion in 2020, which was "anticipated to grow with a healthy growth rate of more than 6.7% over the forecast period 2021-2027." [102]

Notes

  1. ↑ "Point of care test" and "rapid test" could refer to "rapid antigen test" but could also refer to tests that use PCR or other technologies.
  2. ↑ The study by Pecoraro et al found a pooled false-negative rate for PCR of 0.12, which implies a sensitivity of 0.88.

Related Research Articles

<span class="mw-page-title-main">Seroconversion</span> Development of specific antibodies in the blood serum as a result of infection or immunization

In immunology, seroconversion is the development of specific antibodies in the blood serum as a result of infection or immunization, including vaccination. During infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but the antibody is absent. During seroconversion, the antibody is present but not yet detectable. After seroconversion, the antibody is detectable by standard techniques and remains detectable unless the individual seroreverts, in a phenomenon called seroreversion, or loss of antibody detectability, which can occur due to weakening of the immune system or decreasing antibody concentrations over time. Seroconversion refers the production of specific antibodies against specific antigens, meaning that a single infection could cause multiple waves of seroconversion against different antigens. Similarly, a single antigen could cause multiple waves of seroconversion with different classes of antibodies. For example, most antigens prompt seroconversion for the IgM class of antibodies first, and subsequently the IgG class.

<span class="mw-page-title-main">Point-of-care testing</span> Diagnostic testing performed at or near the point of care

Point-of-care testing (POCT), also called near-patient testing or bedside testing, is defined as medical diagnostic testing at or near the point of care—that is, at the time and place of patient care. This contrasts with the historical pattern in which testing was wholly or mostly confined to the medical laboratory, which entailed sending off specimens away from the point of care and then waiting hours or days to learn the results, during which time care must continue without the desired information.

<span class="mw-page-title-main">Lateral flow test</span> Immunochromatographic testing devices

A lateral flow test (LFT), is an assay also known as a lateral flow device (LFD), lateral flow immunochromatographic assay, or rapid test. It is a simple device intended to detect the presence of a target substance in a liquid sample without the need for specialized and costly equipment. LFTs are widely used in medical diagnostics in the home, at the point of care, and in the laboratory. For instance, the home pregnancy test is an LFT that detects a specific hormone. These tests are simple and economical and generally show results in around five to thirty minutes. Many lab-based applications increase the sensitivity of simple LFTs by employing additional dedicated equipment. Because the target substance is often a biological antigen, many lateral flow tests are rapid antigen tests.

<span class="mw-page-title-main">Rapid antigen test</span> Fast medical lateral flow test

A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT), antigen rapid test (ART), or loosely just a rapid test, is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. RATs are a type of lateral flow test detecting antigens, rather than antibodies or nucleic acid. Rapid tests generally give a result in 5 to 30 minutes, require minimal training or infrastructure, and have significant cost advantages. Rapid antigen tests for the detection of SARS-CoV-2, the virus that causes COVID-19, have been commonly used during the COVID-19 pandemic.

<span class="mw-page-title-main">COVID-19</span> Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. Most scientists believe the SARS-CoV-2 virus entered into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. Social and environmental factors including climate change, natural ecosystem destruction and wildlife trade increased the likelihood of such zoonotic spillover. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

<span class="mw-page-title-main">COVID-19 testing</span> Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2, the virus that cases COVID-19 and is responsible for the COVID-19 pandemic. The two main types of tests detect either the presence of the virus or antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Viral disease testing is the use of a variety of testing techniques for a variety of purposes, including diagnosing conditions, assessing immunity and understanding disease prevalence. The primary approaches include DNA/RNA tests, serological tests and antigen tests.

<span class="mw-page-title-main">Coronavirus breathalyzer</span> Diagnostic medical device

A coronavirus breathalyzer is a diagnostic medical device enabling the user to test with 90% or greater accuracy the presence of severe acute respiratory syndrome coronavirus 2 in an exhaled breath. As of the first half of 2020, the idea of a practical coronavirus breathalyzer was concomitantly developed by unrelated research groups in Australia, Canada, Finland, Germany, Indonesia, Israel, Netherlands, Poland, Singapore, United Kingdom and USA.

The AbC-19 rapid antibody test is an immunological test for COVID-19 exposure developed by the UK Rapid Test Consortium and manufactured by Abingdon Health. It uses a lateral flow test to determine whether a person has IgG antibodies to the SARS-CoV-2 virus that causes COVID-19. The test uses a single drop of blood obtained from a finger prick and yields results in 20 minutes. The sensitivity of this test is 98.03% while the specificity is 99.56%. This test is paired with an easy-to-use mobile app which allows a trained professional to generate an antibody test certificate for storing on a person's smartphone.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.

<span class="mw-page-title-main">Novavax COVID-19 vaccine</span> Vaccine against COVID-19

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.

<span class="mw-page-title-main">Variants of SARS-CoV-2</span> Notable variants of SARS-CoV-2

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

Curative Inc. is a health care startup company best known for scaling COVID-19 testing and COVID-19 vaccinations during the COVID-19 pandemic. In September 2022, Curative Inc. launched Curative Insurance Company, a new health insurance plan featuring no copays and no deductibles. Headquartered in Austin, Texas, with employees throughout the United States, the company was founded in January 2020 by Fred Turner, Isaac Turner, and Vlad Slepnev to create new diagnostic tests for sepsis and to improve outcomes for sepsis patients. In response to an urgent, unmet need for COVID-19 test development and production in the United States, Curative rapidly shifted focus in March 2020. The company's research team developed a new test for SARS-CoV-2 that utilized oral swabs rather than nasopharyngeal swabs. The Curative test was designed with a scalable process and opportunities to reduce healthcare worker exposure risk, and therefore the amount of personal protective equipment (PPE) used. An independent manufacturing and supply chain model was adopted to avoid competing with existing COVID-19 test companies for limited supplies and laboratory capacity.

<span class="mw-page-title-main">Anne Wyllie</span> New Zealand microbiologist and epidemiologist

Anne Louise Wyllie is a New Zealand microbiologist who was the lead author of a 2020 research article which led to the development of the SalivaDirect PCR method of testing saliva for SARS-CoV-2, the virus that causes COVID-19. She has also worked on community studies to better understand pneumococcal disease. She is a research scientist in epidemiology with the Public Health Modeling Unit at Yale University.

<span class="mw-page-title-main">SARS-CoV-2 Omicron variant</span> Type of the virus first detected in November 2021

Omicron (B.1.1.529) is a variant of SARS-CoV-2 first reported to the World Health Organization (WHO) by the Network for Genomics Surveillance in South Africa on 24 November 2021. It was first detected in Botswana and has spread to become the predominant variant in circulation around the world. Following the original B.1.1.529 variant, several subvariants of Omicron have emerged including: BA.1, BA.2, BA.3, BA.4, and BA.5. Since October 2022, two subvariants of BA.5 called BQ.1 and BQ.1.1 have emerged.

<span class="mw-page-title-main">Nirmatrelvir/ritonavir</span> Antiviral combination medication

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Nirmatrelvir inhibits SARS-CoV-2 main protease, while ritonavir is a strong CYP3A inhibitor, slowing down nirmatrelvir metabolism and therefore boosting its effect. It is taken by mouth.

References

  1. 1 2 Kahanec M, Lafférs L, Schmidpeter B (2021). "The impact of repeated mass antigen testing for COVID-19 on the prevalence of the disease". J Popul Econ. 34 (4): 1105–1140. doi: 10.1007/s00148-021-00856-z . PMC   8241209 . PMID   34219976.
  2. 1 2 3 Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. Interim guidance (Report). World Health Organization (WHO). 9 March 2022. hdl: 10665/352350 . WHO/2019-nCoV/Ag-RDTs/Self_testing/2022.1.
  3. 1 2 3 4 5 6 7 8 Khalid MF, Selvam K, Jeffry AJ, Salmi MF, Najib MA, Norhayati MN, et al. (4 January 2022). "Performance of Rapid Antigen Tests for COVID-19 Diagnosis: A Systematic Review and Meta-Analysis". Diagnostics. 12 (1): 110. doi: 10.3390/diagnostics12010110 . PMC   8774565 . PMID   35054277.
  4. 1 2 3 4 5 6 7 Brümmer LE, Katzenschlager S, McGrath S, Schmitz S, Gaeddert M, Erdmann C, et al. (26 May 2022). "Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors". PLOS Med. 19 (5): e1004011. doi: 10.1371/journal.pmed.1004011 . PMC   9187092 . PMID   35617375.
  5. 1 2 3 4 5 6 7 Tapari A, Braliou GG, Papaefthimiou M, Mavriki H, Kontou PI, Nikolopoulos GK, et al. (4 June 2022). "Performance of Antigen Detection Tests for SARS-CoV-2: A Systematic Review and Meta-Analysis". Diagnostics. 12 (6): 1388. doi: 10.3390/diagnostics12061388 . PMC   9221910 . PMID   35741198.
  6. ↑ Pecoraro V, Negro A, Pirotti T, Trenti T (2022). "Estimate false-negative RT-PCR rates for SARS-CoV-2. A systematic review and meta-analysis". Eur J Clin Invest. 52 (2): e13706. doi: 10.1111/eci.13706 . PMC   8646643 . PMID   34741305.
  7. ↑ Pu R, Liu S, Ren X, Shi D, Ba Y, Huo Y, et al. (2022). "The screening value of RT-LAMP and RT-PCR in the diagnosis of COVID-19: systematic review and meta-analysis". J Virol Methods. 300: 114392. doi: 10.1016/j.jviromet.2021.114392 . PMC   8629515 . PMID   34856308.
  8. ↑ "Oxford University and PHE confirm lateral flow tests show high specificity and are effective at identifying most individuals who are infectious". Oxford University. 11 November 2020. Archived from the original on 17 July 2021. Retrieved 19 May 2021.
  9. ↑ Guglielmi G (2020). "Fast coronavirus tests: what they can and can't do". Nature. 585 (7826): 496–498. Bibcode:2020Natur.585..496G. doi: 10.1038/d41586-020-02661-2 . PMID   32939084.
  10. 1 2 3 "WHO COVID-19: Case Definitions". World Health Organization (WHO). 16 December 2020. Archived from the original on 7 July 2022. Retrieved 8 July 2022.
  11. ↑ "Case definition and clinical testing guidelines for COVID-19". New Zealand Ministry of Health – Manatū Hauora. 30 June 2022. Archived from the original on 9 July 2022. Retrieved 8 July 2022.
  12. 1 2 Paltiel AD, Zheng A, Walensky RP (2020). "Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States". JAMA Netw Open. 3 (7): e2016818. doi: 10.1001/jamanetworkopen.2020.16818 . PMC   7395236 . PMID   32735339.
  13. 1 2 Mina MJ, Parker R, Larremore DB (2020). "Rethinking Covid-19 Test Sensitivity – A Strategy for Containment". The New England Journal of Medicine. 383 (22): e120. doi: 10.1056/NEJMp2025631 . PMID   32997903.
  14. 1 2 Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. (2021). "Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening". Science Advances. 7 (1): eabd5393. Bibcode:2021SciA....7.5393L. doi: 10.1126/sciadv.abd5393 . PMC   7775777 . PMID   33219112.
  15. ↑ "North Jakarta to provide rapid tests for people in flood shelters". The Jakarta Post. 2 December 2020. Archived from the original on 26 December 2022. Retrieved 11 July 2022.
  16. ↑ "Covid-19: Charities send food to stranded truckers". BBC News. 23 December 2020. Archived from the original on 6 December 2022. Retrieved 11 July 2022.
  17. ↑ Rawlinson K, Halliday J (24 December 2020). "Army to take over Covid testing for hauliers trapped near Dover". The Guardian. ISSN   0261-3077. Archived from the original on 14 November 2021. Retrieved 11 July 2022.
  18. ↑ "COVID-19: Raw anger among lorry drivers in Dover as coronavirus testing fails to ease tensions". Sky News. 24 December 2020. Archived from the original on 14 November 2021. Retrieved 11 July 2022.
  19. ↑ "COVID-19 diagnostics: MSF welcomes more affordable rapid tests for lower- and middle-income countries – World". ReliefWeb. 29 January 2021. Archived from the original on 14 November 2021. Retrieved 11 July 2022.
  20. ↑ Glenn A (7 December 2020). "Pharmacies in Spain to Roll out Rapid Tests for COVID-19". Euro Weekly News. Archived from the original on 18 May 2022. Retrieved 11 July 2022.
  21. ↑ Dorn S (12 December 2020). "Barcelona hosts concert for 500 residents in COVID rapid-test experiment". New York Post. Archived from the original on 4 July 2022. Retrieved 11 July 2022.
  22. ↑ "The Albanian government has approved rapid Covid testing for Unum Festival 2021". Crack Magazine. 2 December 2020. Archived from the original on 20 May 2022. Retrieved 11 July 2022.
  23. ↑ "Rapid tests are not the solution to restart normal life, expert says". The Brussels Times. 22 December 2020. Archived from the original on 25 May 2022. Retrieved 11 July 2022.
  24. ↑ "Lateral flow testing – new rapid tests to detect COVID-19 – Public health matters". publichealthmatters.blog.gov.uk. 8 December 2020. Archived from the original on 5 August 2021. Retrieved 11 July 2022.
  25. ↑ Service RF (22 May 2020). "Coronavirus antigen tests: quick and cheap, but too often wrong?". Science. Archived from the original on 11 July 2022. Retrieved 10 July 2022.
  26. ↑ Saxena R (17 August 2020). "Why India's rapid antigen tests for coronavirus are like 'flipping a coin'". ThePrint . Archived from the original on 21 August 2022. Retrieved 10 July 2022.
  27. ↑ Halliday J, Pidd H (22 December 2020). "Plans for 30-minute Covid testing in England halted amid accuracy fears". The Guardian. Archived from the original on 11 July 2022. Retrieved 10 July 2022.
  28. 1 2 3 Antigen-detection in the diagnosis of SARS-CoV-2 infection. Interim guidance (Report). World Health Organization (WHO). 6 October 2021. hdl: 10665/345948 . WHO/2019-nCoV/Antigen_Detection/2021.1.
  29. 1 2 3 4 Chu VT, Schwartz NG, Donnelly MA, Chuey MR, Soto R, Yousaf AR, et al. (2022). "Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection". JAMA Intern Med. 182 (7): 701–709. doi: 10.1001/jamainternmed.2022.1827 . PMC   9055515 . PMID   35486394.
  30. ↑ "Rapid evaluation confirms lateral flow devices effective in detecting new COVID-19 variant". GOV.UK. Archived from the original on 5 October 2021. Retrieved 4 July 2022.
  31. 1 2 Bourassa L, Perchetti GA, Phung Q, Lin MJ, Mills MG, Roychoudhury P, et al. (2021). "A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance". J Clin Virol. 141: 104900. doi: 10.1016/j.jcv.2021.104900 . PMC   8219478 . PMID   34171548.
  32. ↑ Bayart JL, Degosserie J, Favresse J, Gillot C, Didembourg M, Djokoto HP, et al. (2022). "Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant". Viruses. 14 (4): 654. doi: 10.3390/v14040654 . PMC   9031584 . PMID   35458384.
  33. ↑ Lorch M (5 July 2021). "How children are spoofing Covid-19 tests with soft drinks". BBC. Archived from the original on 5 June 2022. Retrieved 3 July 2022.
  34. 1 2 Patriquin G, Davidson RJ, Hatchette TF, Head BM, Mejia E, Becker MG, et al. (2021). "Generation of False-Positive SARS-CoV-2 Antigen Results with Testing Conditions outside Manufacturer Recommendations: A Scientific Approach to Pandemic Misinformation". Microbiol Spectr. 9 (2): e0068321. doi:10.1128/Spectrum.00683-21. PMC   8528119 . PMID   34668722.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  35. ↑ Holliday I (29 January 2021). "Rapid tests could have prevented half of B.C. care home deaths in 2020, modelling suggests". CTVNews . Archived from the original on 3 August 2022. Retrieved 7 July 2022.
  36. ↑ Johnson-Arbor K, Reid N, Smolinske S (25 January 2022). "Human toxicity from COVID-19 rapid home test kits". The American Journal of Emergency Medicine . 57: 215–216. doi:10.1016/j.ajem.2022.01.048. PMC   8786400 . PMID   35105473.
  37. ↑ Affatato S (February 2004). "Sodium-azide versus ProClin 300: influence on the morphology of UHMWPE particles generated in laboratory tests". Biomaterials. 25 (5): 835–842. doi:10.1016/s0142-9612(03)00603-3. PMID   14609672.
  38. ↑ "Rapid antigen test kits and potential exposure to hazardous substances". Government of Canada . 24 February 2022. Archived from the original on 24 January 2024. Retrieved 24 January 2024.
  39. 1 2 Drain PK (2022). "Rapid Diagnostic Testing for SARS-CoV-2". N Engl J Med. 386 (3): 264–272. doi:10.1056/NEJMcp2117115. PMC   8820190 . PMID   34995029.
  40. ↑ "EU Common list of COVID-19 rapid antigen tests" (PDF). European Commission, Directorate-General for Health and Food Safety. 10 June 2022. Archived from the original (PDF) on 5 July 2022. Retrieved 6 July 2022.
  41. 1 2 3 4 5 Shirazi S, Stanford CM, Cooper LF (2021). "Testing for COVID-19 in dental offices: mechanism of action, application and interpretation of laboratory and point-of-care screening tests". The Journal of the American Dental Association. 152 (7): 514–525.e8. doi:10.1016/j.adaj.2021.04.019. ISSN   0002-8177. PMC   8096195 . PMID   34176567.
  42. 1 2 "How COVID-19 lateral flow tests work". Welsh Government. 30 June 2022. Archived from the original on 13 July 2022. Retrieved 6 July 2022.
  43. 1 2 Frew E, Roberts D, Barry S, Holden M, Restell Mand A, Mitsock E, et al. (2021). "A SARS-CoV-2 antigen rapid diagnostic test for resource limited settings". Sci Rep. 11 (1): 23009. Bibcode:2021NatSR..1123009F. doi:10.1038/s41598-021-02128-y. PMC   8626481 . PMID   34837001.
  44. ↑ Hahn SM, Shuren JE (9 May 2020). "Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients". U.S. Food and Drug Administration (FDA). Archived from the original on 27 May 2020. Retrieved 4 July 2022.
  45. ↑ "Trump Administration Will Deploy 150 Million Rapid Tests in 2020". United States Department of Health and Human Services. 27 August 2020. Archived from the original on 28 August 2020. Retrieved 4 July 2022.{{cite web}}: CS1 maint: unfit URL (link)
  46. ↑ Blad E (9 October 2020). "Why Rapid Coronavirus Tests in Schools May Not Be the 'Game Changer' Some Officials Hope For". Education Week . Archived from the original on 13 July 2022. Retrieved 12 July 2022.
  47. ↑ Iacobucci G, Coombes R (2020). "Covid-19: Government plans to spend £100bn on expanding testing to 10 million a day". BMJ. 370: m3520. doi: 10.1136/bmj.m3520 . PMID   32907851. A spokesperson for the Department of Health and Social Care said, '… we are going further by investing £500m in next generation tests, like… rapid turnaround tests that can deliver results in just 20 minutes.'
  48. 1 2 3 Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance (Report). World Health Organization (WHO). 11 September 2020. hdl: 10665/334253 . WHO/2019-nCoV/Antigen_Detection/2020.1.
  49. ↑ Tasker JP (6 October 2020). "Health Canada approves 1st rapid antigen COVID-19 test, feds plan to buy 20 million". CBC News. Archived from the original on 11 July 2022. Retrieved 4 July 2022.
  50. 1 2 Rubin R (2020). "The Challenges of Expanding Rapid Tests to Curb COVID-19". JAMA. 324 (18): 1813–1815. doi: 10.1001/jama.2020.21106 . PMID   33084882.
  51. ↑ "Huge demand for COVID-19 rapid antigen testing may face manufacturing constraints". Modern Healthcare. 8 October 2020. Archived from the original on 14 June 2022. Retrieved 10 July 2022.
  52. ↑ Donn N (27 October 2020). "Portugal rolls out 'rapid tests' to help stem outbreaks in schools and OAP homes". Portugal Resident. Archived from the original on 14 November 2021. Retrieved 12 July 2022.
  53. ↑ "Oxford University and PHE confirm lateral flow tests show high specificity and are effective at identifying most individuals who are infectious". University of Oxford. 11 November 2020. Archived from the original on 17 July 2021. Retrieved 4 July 2022.
  54. 1 2 Peto T, UK COVID-19 Lateral Flow Oversight Team (2021). "COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing". eClinicalMedicine. 36: 100924. doi:10.1016/j.eclinm.2021.100924. PMC   8164528 . PMID   34101770.
  55. ↑ Mahase E (December 2020). "Covid-19: Mass testing in Slovakia may have helped cut infections". BMJ. 371: m4761. doi: 10.1136/bmj.m4761 . PMID   33293348.
  56. ↑ Agence France-Presse (2 November 2020). "Slovakia carries out Covid mass testing of two-thirds of population". The Guardian. ISSN   0261-3077. Archived from the original on 16 July 2021. Retrieved 11 July 2022.
  57. ↑ Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, Jarčuška P, et al. (2021). "The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia". Science. 372 (6542): 635–641. Bibcode:2021Sci...372..635P. doi: 10.1126/science.abf9648 . PMC   8139426 . PMID   33758017.
  58. ↑ Boseley S, Elgot J (2 November 2020). "Liverpool to pioneer UK's first attempt at mass Covid testing". The Guardian. ISSN   0261-3077. Archived from the original on 1 August 2021. Retrieved 11 July 2022.
  59. ↑ Littlejohns P (6 November 2020). "The UK is trialling a lateral flow test for mass Covid-19 diagnosis – how does it work?". NS Medical Devices. Archived from the original on 20 May 2021. Retrieved 20 May 2021.
  60. ↑ Sigsworth T (19 November 2020). "Covid-19 updates: University's lateral flow tests available to book from tomorrow". Palatinate. Archived from the original on 19 May 2021. Retrieved 11 July 2022.
  61. ↑ "Covid-19: Universities to oversee student exodus for Christmas". BBC News. 11 November 2020. Archived from the original on 21 April 2022. Retrieved 11 July 2022.
  62. ↑ Serle J (9 November 2020). "NHS staff to get twice-weekly home covid tests with immediate effect". Health Service Journal. Archived from the original on 19 May 2021. Retrieved 11 July 2022.
  63. ↑ "More rapid COVID-19 tests to be rolled out across England". GOV.UK. 10 November 2020. Archived from the original on 6 June 2022. Retrieved 12 July 2022.
  64. ↑ "COVID-19: Care home residents allowed to see family after rapid tests rolled out – 'it was very emotional'". Sky News. 25 December 2020. Archived from the original on 19 May 2021. Retrieved 12 July 2022.
  65. ↑ "£149 million to support increased care home testing". GOV.UK. 23 December 2020. Archived from the original on 14 July 2022. Retrieved 12 July 2022.
  66. ↑ "Mass Testing in Merthyr Tydfil to continue until Friday". 14 December 2020. Archived from the original on 19 May 2021. Retrieved 12 July 2022.
  67. ↑ Wightwick A (10 December 2020). "Results of mass coronavirus testing in Merthyr schools released". WalesOnline. Archived from the original on 25 June 2022. Retrieved 12 July 2022.
  68. ↑ "SARS-CoV-2 Antigen detecting rapid diagnostic test implementation projects". World Health Organization (WHO). 10 November 2020. Archived from the original on 26 February 2021. Retrieved 27 December 2020.
  69. ↑ "Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries". World Health Organization (WHO). 28 September 2020. Archived from the original on 19 July 2021. Retrieved 27 December 2020.
  70. ↑ "COVID-19 Mass Testing in Austria: All Details". Vindobona.org | Vienna International News. Archived from the original on 19 May 2021. Retrieved 27 December 2020.
  71. ↑ "'20,000 a day': How mass testing is working in Austria". www.thelocal.at. 7 December 2020. Archived from the original on 9 December 2020. Retrieved 27 December 2020.
  72. ↑ Gremmels H, Winkel BM, Schuurman R, Rosingh A, Rigter NA, Rodriguez O, et al. (January 2021). "Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection". eClinicalMedicine. 31: 100677. doi: 10.1016/j.eclinm.2020.100677 . PMC   7832943 . PMID   33521610.{{cite journal}}: CS1 maint: overridden setting (link)
  73. ↑ Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, et al. (November 2020). "A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay". Journal of Clinical Virology. 132: 104645. doi:10.1016/j.jcv.2020.104645. PMC   7493757 . PMID   32961429.{{cite journal}}: CS1 maint: overridden setting (link)
  74. ↑ Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, et al. (July 2020). "Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution". Journal of Clinical Microbiology. 58 (8). doi: 10.1128/JCM.01136-20 . PMC   7383552 . PMID   32471894.{{cite journal}}: CS1 maint: overridden setting (link)
  75. ↑ "Rapid COVID-19 Testing Expands to Include Vulnerable Populations in Alberta". thestar.com. 23 December 2020. Archived from the original on 2 February 2022. Retrieved 27 December 2020.
  76. ↑ CoconutsBali (22 December 2020). "Passengers form long queues to take antigen rapid tests in Bali's Ngurah Rai Airport | Coconuts Bali". Coconuts. Archived from the original on 14 November 2021. Retrieved 27 December 2020.
  77. ↑ Pinto R, Iyer M (28 June 2020). "Mumbai: As 15-minutes rapid tests start this week, spike in cases expected". Mumbai News. The Times of India. Archived from the original on 25 September 2022. Retrieved 27 December 2020.
  78. ↑ Haseltine WA (11 December 2020). "Even With A Vaccine, We Still Need Rapid Tests To End Covid-19". Forbes. Archived from the original on 14 November 2021. Retrieved 4 July 2022.
  79. ↑ Dickerson MD, Ditch D (22 December 2020). "9 Things You Need to Know About the $1.4 Trillion Fiscal Year 2021 Omnibus and $900 Billion COVID-19 Package". The Heritage Foundation. Archived from the original on 3 July 2022. Retrieved 4 July 2022.
  80. ↑ "Coronavirus (COVID-19) Update: FDA Issues New Authorization for the BinaxNOW COVID-19 Ag Card Home Test". U.S. Food and Drug Administration (FDA). 16 December 2020. Archived from the original on 22 July 2022. Retrieved 4 July 2022.
  81. ↑ Wan W (16 December 2020). "How do home tests for coronavirus work? Where can I get one?". The Washington Post . Archived from the original on 3 December 2021. Retrieved 4 July 2022.
  82. ↑ Courage KH (18 December 2020). "Rapid at-home Covid-19 tests are finally here. Here's how they could help end the pandemic". Vox. Archived from the original on 26 June 2022. Retrieved 4 July 2022.
  83. ↑ Mahase E (2020). "Covid-19: UK regulator approves lateral flow test for home use despite accuracy concerns". BMJ. 371: m4950. doi: 10.1136/bmj.m4950 . PMID   33361088.
  84. ↑ Woodcock A (5 December 2020). "Negative result in rapid Covid test is not green light to abandon social distancing, top medic warns". The Independent. Archived from the original on 8 July 2022. Retrieved 8 July 2022.
  85. 1 2 "Coronavirus: Commission puts forward rules on rapid antigen tests and secures 20 million tests for Member States". European Commission. 18 December 2020. Archived from the original on 24 April 2021. Retrieved 8 July 2022.
  86. ↑ "Council agrees on strengthening the use of rapid antigen tests and on the mutual recognition of COVID-19 test results". Council of the European Union. 21 January 2021. Archived from the original on 19 May 2021. Retrieved 4 July 2022.
  87. ↑ Biden JR Jr (21 January 2021). "National Strategy for the COVID-19 Response and Pandemic Preparedness" (PDF). White House. Archived (PDF) from the original on 9 July 2022. Retrieved 4 July 2022.
  88. ↑ "Coronavirus (COVID-19) Update: FDA Continues to Advance Over-the Counter and Other Screening Test Development". U.S. Food and Drug Administration (FDA). 31 March 2021. Archived from the original on 3 July 2022. Retrieved 4 July 2022.
  89. 1 2 "Stop Using Innova SARS-CoV-2 Antigen Rapid Qualitative Test: FDA Safety Communication". U.S. Food and Drug Administration (FDA). 10 June 2021. Archived from the original on 25 June 2021. Retrieved 4 July 2022.
  90. ↑ Hale C (18 June 2021). "U.K. doubles down on Innova's rapid COVID-19 test, after FDA urged users to throw it away". FierceBiotech. Archived from the original on 3 July 2022. Retrieved 4 July 2022.
  91. ↑ "Ellume Recalls COVID-19 Home Test for Potential False Positive SARS-CoV-2 Test Results". U.S. Food and Drug Administration (FDA). 16 November 2021. Archived from the original on 7 July 2022. Retrieved 4 July 2022.
  92. 1 2 Diaz J, Naylor B (21 December 2021). "Biden announces free tests and defends the White House response as COVID cases surge". National Public Radio. Washington, D.C. Archived from the original on 12 July 2022. Retrieved 4 July 2022.
  93. ↑ Naylor B (14 January 2022). "You'll be able to order free at-home COVID test kits starting on Wednesday". National Public Radio. Washington, D.C. Archived from the original on 6 July 2022. Retrieved 4 July 2022.
  94. ↑ "Counterfeit At-Home OTC COVID-19 Diagnostic Tests". U.S. Food and Drug Administration (FDA). 29 April 2022. Archived from the original on 6 July 2022. Retrieved 4 July 2022.
  95. 1 2 3 4 5 "FDA Authorizes Marketing of First Home Flu and COVID-19 Combination Test Outside of Emergency Use Authorities" (Press release). U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 8 October 2024. Retrieved 8 October 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  96. ↑ Jakobsen KK, Jensen JS, Todsen T, Tolsgaard MG, Kirkby N, Lippert F, et al. (2021). "Accuracy and cost description of rapid antigen test compared with reverse transcriptase-polymerase chain reaction for SARS-CoV-2 detection". Dan Med J. 68 (7): A03210217. PMID   34169830. Archived from the original on 1 December 2022. Retrieved 10 July 2022.
  97. ↑ Diel R, Hittel N, Nienhaus A (2021). "Point-of-Care COVID-19 Antigen Testing in Exposed German Healthcare Workers-A Cost Model". Int J Environ Res Public Health. 18 (20): 10767. doi: 10.3390/ijerph182010767 . PMC   8536062 . PMID   34682514.
  98. ↑ Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore y Piontti A, et al. (2021). "Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study". Lancet Public Health. 6 (3): e184–e191. doi: 10.1016/S2468-2667(21)00002-5 . PMC   7862022 . PMID   33549196.
  99. ↑ Paltiel AD, Zheng A, Sax PE (2021). "Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission". Ann Intern Med. 174 (6): 803–810. doi: 10.7326/M21-0510 . PMC   9317280 . PMID   33683930.
  100. ↑ "Global COVID-19 Rapid Antigen Test Kits Market Research Report 2022". Market Reports World. 10 June 2022. Archived from the original on 19 February 2023. Retrieved 10 July 2022.
  101. ↑ "COVID-19 Rapid Antigen Test Kits Market - Global Outlook & Forecast 2022-2027". Arizton Advisory & Intelligence. June 2022. Archived from the original on 10 July 2022. Retrieved 10 July 2022.
  102. ↑ "Global COVID-19 Antigen Test Market Size study, by Product & Service (Platforms, Reagents & Kits and Services), by End-Use (Clinics & Hospitals, Home Care, Diagnostic Labs and Others) and Regional Forecasts 2021–2027". Market Study Report. 17 July 2021. Archived from the original on 15 August 2022. Retrieved 10 July 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.